COVID-19 Drug Flexibilities Expiring
April 7, 2021
On March 23, 2020, the Department of Health Care Services (DHCS) received approval of a federal waiver allowing specific flexibilities related to the coronavirus disease 2019 (COVID-19) public health emergency. These flexibilities are set to end on April 20, 2021. As a result, for dates of service on or after April 20, 2021, the following is in effect:
- DHCS will cease to cover and reimburse off-label and/or investigational medications not yet having the required published documentation for use in COVID-19, as listed in Title 22, California Code of Regulations (CCR), Title 22, Sections 51303 and 51313, without an approved Treatment Authorization Request (TAR) or Service Authorization Request (SAR) and all required documentation supporting the medical necessity of off-label and/or investigational use.
- Subcutaneous depot medroxyprogesterone acetate (DMPA-SQ) will remain in the Medi-Cal provider manual and available without a TAR.